Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer’s disease
This study introduces a series of adamantane-derived semicarbazones and hydrazones designed to address multiple pathological features of Alzheimer’s disease (AD). Among the synthesized compounds, 2-pyridinecarboxaldehyde (N-adamantan-1-yl)benzoyl-4-amidohydrazone (compound 10) emerged as a lead candidate, demonstrating potent iron-chelating properties, inhibition of copper(II)-induced β-amyloid aggregation, low cytotoxicity, and antioxidant activity. Additionally, compound 10
June 26, 2025
No Comments